RxDoctor Payments Data

Robert Ondash, MD

Internal Medicine · West Lake Hills, TXNPI 1053320069

Payments from drug & device makers

$8,355in general payments, 2019–2025

Across 494 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$977
  • AstraZeneca$895
  • AbbVie$883
  • GSK$785
  • Lilly USA, LLC$621
  • Amgen$579
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,348100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,355 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$139,634
Medicare patients
347
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$77,946
TrulicityDulaglutide27$33,302
EliquisApixaban27$30,768
FarxigaDapagliflozin Propanediol15$13,738
XareltoRivaroxaban19$13,090
SymbicortBudesonide/Formoterol Fumarate13$2,681
SynthroidLevothyroxine Sodium43$2,582
Levemir FlexpenInsulin Detemir13$2,321
Atorvastatin Calcium257$2,316
Levothyroxine Sodium148$1,780
Estradiol28$1,709
Valsartan52$1,451
Rosuvastatin Calcium136$1,388
Amlodipine Besylate201$1,256
Eszopiclone47$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$977$77,94667 claims
Lilly USA, LLCTrulicity$621$33,30227 claims
PfizerEliquis$446$30,76827 claims
AstraZenecaFarxiga, Symbicort$895$16,41928 claims
AbbVieSynthroid$883$2,58243 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$71$1,780148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in West Lake Hills

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →